"A Quantum Leap In Resources": Millennium CEO Dunsire In A Conversation On The Firm's First Year As Part Of Takeda (Part 1 Of 2)
This article was originally published in PharmAsia News
Executive Summary
On May 14, Millennium Pharmaceuticals marked its one-year anniversary as the Takeda Oncology company.
You may also be interested in...
Looking for Oncology Payoff, Astellas Makes Hostile Bid for Tarceva Maker OSI
Astellas Pharma is going hostile again. The Japanese drug maker launched a $3.5 billion unsolicited bid for OSI Pharmaceuticals on March 1 to gain a foothold in the oncology market
Looking for Oncology Payoff, Astellas Makes Hostile Bid for Tarceva Maker OSI
Astellas Pharma is going hostile again. The Japanese drug maker launched a $3.5 billion unsolicited bid for OSI Pharmaceuticals on March 1 to gain a foothold in the oncology market
Standing Alone While Standing Together: A Conversation With Millennium CEO Dunsire (Part 2 Of 2)
Millennium Pharmaceuticals reached its one-year anniversary as the Takeda Oncology Company on May 14. Millennium Pharmaceuticals CEO Deborah Dunsire sat down recently with "The Pink Sheet" DAILY for a conversation about the changes seen in that first year.